Johnson & Johnson and Vanda Pharmaceuticals side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Johnson & Johnson | Vanda Pharmaceuticals |
|---|---|---|
| Phase 1 | Johnson & Johnson: 26 of its 56 programs at phase 1
and 21 more — sign in to see them all | 00% |
| Phase 2 | Johnson & Johnson: 8 of its 56 programs at phase 2
and 3 more — sign in to see them all | Vanda Pharmaceuticals: 3 of its 9 programs at phase 2
|
| Phase 3 | Johnson & Johnson: 18 of its 56 programs at phase 3
and 13 more — sign in to see them all | Vanda Pharmaceuticals: 4 of its 9 programs at phase 3
|
| Approved, new studies | Johnson & Johnson: 4 of its 56 programs at approved, new studies
| Vanda Pharmaceuticals: 2 of its 9 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson26 readouts · 8 phase 3 | Johnson & Johnson, Nov ’26: 1 program whose next study reaches primary completion
| Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3
and 4 more — sign in to see them all | Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion
| Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3
| Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion
| Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion
| · | Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion
| · | Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion
|
| Vanda Pharmaceuticals3 readouts · 2 phase 3 | · | Vanda Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3
| · | · | Vanda Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion
| · | · | · | · | · | · | · |
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Johnson & Johnson
New programs 1
- JNJ-99220732phase 1 · first study · Nov 12 · Neoplasms
Reached a new phase 2
- Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915phase 3 · Oct 26 · Prostatic Neoplasms
- deulumateperonephase 3 · Sep 2 · Generalized Anxiety Disorder
Study stopped 0
None
Primary completion later 3
- bleximenibphase 2 · Feb 2027 → Dec 2028 (+22 mo) · moved Nov 4 · NCT04811560
- teclistamabapproved, new study · Nov 2026 → Feb 2027 (+3 mo) · moved Nov 3 · NCT07030517
- Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Dec 2026 → Jun 2027 (+6 mo) · moved Oct 26 · NCT06150157
Vanda Pharmaceuticals
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 1
- iloperidoneapproved, new study · Mar 2026 → Dec 2028 (+33 mo) · moved Oct 1 · NCT05648591
Where they overlap
Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Johnson & Johnson | Vanda Pharmaceuticals |
|---|---|---|
| DRD2 | lumateperonerule | iloperidonerule |
| HTR2A | lumateperonerule | iloperidonerule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Johnson & Johnson: 4).